EXPERT REACTION: Analysis finds steroids help treat critically ill COVID-19 patients
Meta-analysis: This type of study involves using statistics to combine the data from multiple previous studies to give an overall result. The reliability of a meta-analysis depends on both the quality and similarity of the individual studies being grouped together.
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
Treating critically ill COVID-19 patients with corticosteroids, including dexamethasone, methylprednisolone, and hydrocortisone, is associated with improved survival, a new meta-analysis with Australian and NZ authors has found. Looking at seven randomised clinical trials involving 1703 patients from around the world, including a trial run in Australia and New Zealand, researchers found corticosteroid treatment resulted in fewer deaths, longer survival times and fewer adverse events, compared with a placebo or usual care. The meta-analysis is being published alongside the results from three of the trials featured in the meta-analysis, including the REMAP-CAP study led by Australia and involving New Zealand researchers, as well as new guidelines from the World Health Organization regarding use of corticosteroids for treatment of critically ill COVID-19 patients.
Link to research (DOI): 10.1001/jama.2020.17023
Organisation/s: Australian Science Media Centre, Monash University, Health Research Council of New Zealand (HRC)
These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.
This paper is a survey of primary studies that used systemic (not inhaled) steroids on severely ill COVID-19 patients. Across these studies, deaths fell from 40 to 32 percent. The results are encouraging and support the earlier findings of the RECOVERY study at Oxford University.
It's important to understand that these steroids were used as a treatment for people who are severely ill - generally in intensive care. This group is a small proportion of people who get COVID-19. However, these outcomes contribute to a larger picture that is emerging on a role for anti-inflammatory treatments generally for COVID-19 in the community.
The STOIC (STerOids In COVID-19) trial at Oxford, with which I am involved, is investigating a potential role for inhaled corticosteroids as a treatment in very early stage COVID-19, rather than when patients are critically ill. Unlike systemic steroids, inhaled corticosteroids work directly on inflamed lung cells.
Professor Richard Head is a Pharmacologist and currently Adjunct Professor in the Clinical and Health Sciences Unit at the University of South Australia
This is a very timely and important study that brings together the results of recent clinical trials that have looked at the effects of a well-established older class of drugs, the corticosteroids, in critically ill patients with COVID-19 disease. Their analysis demonstrates a large and significant decrease in mortality with this class of drug in critically ill patients with COVID at 28 days.
Four aspects to these findings are very important. Firstly It provides a much needed treatment option for those involved in critically ill patient treatment in this pandemic. In distinction, there are no other drugs with prospective and randomised rigorous evidence to support use.
Secondly, it highlights the importance of thoroughly examining our existing portfolio of drugs, such as steroids and other anti-inflammatory therapies, for beneficial effects in this COVID-19 disease.
Thirdly, it amplifies the critical role not just of the drug, but of pathophysiology, dose, timing and route of administration of drug, issues that were clearly ignored with the push to use hydroxychloroquine and HIV therapies. Importantly it also illustrates the power of treating the primarily pulmonary (but also other organ) inflammatory storm in COVID-19 disease. This focus on treating the host response (rather than antiviral activity), pioneered by Professor Fedson focuses on treatments that reduce death or morbidity, by dampening down the immune system. A very encouraging study and one which should provide additional stimulus for similar re-purposing research to be conducted in Australia.
This study pools together seven studies looking at the effects of corticosteroids on survival in critically ill COVID-19 patients. It shows a benefit across three steroid drugs.
Why do these drugs work?
These drugs dampen down the immune system response to COVID. In some people with COVID, the immune system generates a hyper-response, for reasons that are not clearly understood. This severe reaction results in the body attacking itself and generating severe symptoms and death. The steroids calm this reaction down – just like pruning a hedge. We don’t want to kill the hedge (that is, completely stop the immune system), we want to trim it back so it is not running rampant, but rather is controlled and still able to function.
Can we use these drugs as a preventative for COVID-19?
The short answer is ‘No’. These drugs (like hydroxychloroquine) are immunosuppressants – that is, they suppress the immune system. They are useful when the immune system is running rampant, but using them in an otherwise healthy person will suppress their immune system and might leave them more vulnerable to an infection – including COVID or any other pathogen, for example influenza. All drugs also have side effects, so we need to make sure that the benefits of use will outweigh the risks associated with their use
Today [Thursday] an important meta-analysis on seven randomized clinical trials on corticosteroids, a cheap and readily available treatment for COVID-19, was published in JAMA. This study was commissioned from the WHO to provide clinical guidance on the use of corticosteroids for COVID-19. This meta-analysis on 1,703 COVID-19 patients shows that administration of systemic corticosteroid treatment regimen for critically ill patients reduces the mortality at 28 days, compared to placebo or standard of care without serious adverse events. The benefit is higher for patients receiving oxygen rather than mechanical ventilation at the start of this treatment regimen.
This meta-analysis confirms the results from the UK RECOVERY trial that showed a reduction of mortality on critically ill COVID-19 patients in ICU. Overall this report, and previous trials, provide important and significant evidence for a wide adoption of systemic corticosteroid administration to COVID-19 patients at hospital receiving respiratory support. Following this report, I would anticipate recommendations from the WHO to widely implement the use of systemic corticosteroids for critically ill COVID-19 patients requiring oxygen as a standard of care.
For us to move forward and live alongside COVID-19 we will need not only a viable vaccine, but also effective treatments for a virus that has significant morbidity. The results from this study are very timely, as they provide compelling data on a potential treatment for COVID-19.
This report from the WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group represents 'best practice' in systematic evaluation of evidence in a rapidly evolving situation. Researchers from all trials of corticosteroids in COVID-19 actively participated by providing data as soon as possible, before the primary studies had been fully analysed and reported.
The result is robust and we can now confidently state that corticosteroids should be used in critically ill patients with respiratory failure due to COVID-19. There remain questions of which steroid should be used (and the studies examined dexamethasone, methylprednisolone and hydrocortisone) and precisely what dose should be used, and future research should be targeted to answer these questions.
The authors conducted a prospective meta-analysis, which are a number of randomized clinical trials that are included before the results of any of those studies become known.
The study herein pooled data from seven clinical studies from 12 different countries to estimate the association between the use of corticosteroids compared to usual care or placebo and the 28-day all-cause mortality in critically ill patients. On the one hand, pooling the results from seven different studies paints a bigger picture than looking at one study; however, as the different studies are fundamentally quite different, this makes the analysis of the pooled study not as straight forward.
In this study, different corticosteroids in low and high concentrations (dexamethasone at low and high doses, low-dose hydrocortisone, and high-dose methylprednisolone) were used.
Based on the results of the UK-based Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial the Task Force for the Australian guideline for the clinical care of people with COVID-19 recommend the use low dose dexamethasone (6 mg daily intravenously or orally) for up to 10 days in adults with COVID-19 who are receiving oxygen (including mechanically ventilated patients); but currently have a conditional recommendation against using dexamethasone in adults with COVID-19 who do not require oxygen therapy.
In this study, the authors leave a major question unanswered: What is the optimal dose?
Low-dose corticosteroids have been shown to be beneficial. But using high-dose corticosteroids for COVID-19 has been associated with the risk of secondary infections, long-term complications and prolonged virus shedding.
Corticosteroid treatment is a double-edged sword but the evidence shows that severely ill patients benefit from corticosteroid treatment.
Media contact details for this story are only visible to registered journalists.